These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16797400)

  • 1. Surrogate markers in clinical studies: problems solved or created?
    Manns B; Owen WF; Winkelmayer WC; Devereaux PJ; Tonelli M
    Am J Kidney Dis; 2006 Jul; 48(1):159-66. PubMed ID: 16797400
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biological markers: utilization in drug development and approval].
    Gueyffier F; Dib M; Boissel JP
    Therapie; 2001; 56(4):355-61. PubMed ID: 11677852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Establishing a national biomarker database: utility and incentives.
    Cummings JL
    Alzheimers Dement; 2009 Mar; 5(2):108-13. PubMed ID: 19328437
    [No Abstract]   [Full Text] [Related]  

  • 4. Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus.
    Schiffenbauer J; Hahn B; Weisman MH; Simon LS
    Arthritis Rheum; 2004 Aug; 50(8):2415-22. PubMed ID: 15334452
    [No Abstract]   [Full Text] [Related]  

  • 5. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.
    Biomarkers Definitions Working Group.
    Clin Pharmacol Ther; 2001 Mar; 69(3):89-95. PubMed ID: 11240971
    [No Abstract]   [Full Text] [Related]  

  • 6. Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
    Cohn J; Cleland JG; Lubsen J; Borer JS; Steg PG; Perelman M; Zannad F
    J Card Fail; 2009 Apr; 15(3):199-205. PubMed ID: 19327621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
    Lassere MN; Johnson KR; Boers M; Tugwell P; Brooks P; Simon L; Strand V; Conaghan PG; Ostergaard M; Maksymowych WP; Landewe R; Bresnihan B; Tak PP; Wakefield R; Mease P; Bingham CO; Hughes M; Altman D; Buyse M; Galbraith S; Wells G
    J Rheumatol; 2007 Mar; 34(3):607-15. PubMed ID: 17343307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate and mediating endpoints: current status and future directions.
    Prentice RL
    J Natl Cancer Inst; 2009 Feb; 101(4):216-7. PubMed ID: 19211455
    [No Abstract]   [Full Text] [Related]  

  • 10. Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches.
    Lassere M; Johnson K; Hughes M; Altman D; Buyse M; Galbraith S; Wells G
    J Rheumatol; 2007 Mar; 34(3):616-9. PubMed ID: 17343308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hotel-based rheumatology, and more.
    Leeb BF
    J Rheumatol; 2009 Feb; 36(2):455-6; author reply 456-7. PubMed ID: 19208582
    [No Abstract]   [Full Text] [Related]  

  • 12. Documentation of endpoint prevention with combination therapy in hypertension is urgently needed.
    Kjeldsen SE; Oparil S; Hedner T; Narkiewicz K
    Blood Press; 2007; 16(1):4-5. PubMed ID: 17453745
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of treatment benefits: clinical endpoints relevant to patients.
    Prescrire Int; 2008 Dec; 17(98):260. PubMed ID: 19425279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dealing with multiple endpoints.
    Dueck A; Novotny PJ
    Curr Probl Cancer; 2006; 30(6):298-306. PubMed ID: 17123881
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Clinical endpoints in peripheral endovascular revascularisation trials: a case for standardized definitions.
    Golledge J; Leicht A; Crowther R; Askew C; Gibbs H; Walker PJ
    Eur J Vasc Endovasc Surg; 2009 Apr; 37(4):497; author reply 497-8. PubMed ID: 19213579
    [No Abstract]   [Full Text] [Related]  

  • 16. Surrogate endpoints and drug approval.
    Somberg J
    Am J Ther; 2006; 13(5):388. PubMed ID: 16988531
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolic approach in heart failure: rethinking how we translate from theory to clinical practice.
    Tang WH
    J Am Coll Cardiol; 2006 Sep; 48(5):999-1000. PubMed ID: 16949493
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug markers questioned.
    Ledford H
    Nature; 2008 Apr; 452(7187):510-1. PubMed ID: 18385695
    [No Abstract]   [Full Text] [Related]  

  • 19. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
    Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
    Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disability as an outcome in MS clinical trials.
    Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
    Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.